RAS Cell Surfaces
Antibodies can target cancer cells with extreme specificity by binding targets displayed on cell surfaces. The goal of our group is to discover cell surface proteins that are enriched or unique to cancers driven by mutated RAS that could be targeted by drugs, antibodies, antibody-drug conjugates, or nanoparticles at the cell surface.
We have developed protocols for enrichment of cell-surface glycoproteins on cultured cells and tumor samples.
We have identified proteins enriched in cells expressing mutant KRAS (publication submitted).
We are collaborating with outside experts to validate and exploit our leads with antibodies and genetic screens.
- Validate methods to identify cell surface proteins by mass spectrometry
- Identify proteins enriched in or unique to the surfaces of cells expressing oncogenic KRAS from cell lines or mouse xenografts
- Validate hits by immunostaining or antibody phage display
Tools We Use
- Mass spectroscopy-based proteomics
- Cell-surface protein enrichment using hydrazide chemistry
- Mouse tumor models
- Immunofluorescence microscopy
CollaborationsThe RAS Cell Surfaces Group has collaborated with:
University of California, San Francisco
University of North Carolina, Chapel Hill
University of Toronto
For more information, contact the RAS Cell Surfaces Group team lead:
Dr. Gordon Whiteley